Pharmafile Logo
Pharmafocus logo
Advanced Search

wet AMD

Showing 4 posts of 19 posts found.

Novartis

Novartis cuts Lucentis price amid growing pressure

October 7, 2011
Sales and Marketing Lucentis, wet AMD

Novartis has been forced to cut the Swiss price of its eye drug Lucentis by 30% after sharp negotiations with …

News

Government wrong to push for Avastin in eye disease, says charity

May 12, 2011
Research and Development, Sales and Marketing Lucentis, RNIB, avastin, wet AMD

The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …

News
Roche's Avastin (bevacizumab)

Avastin as effective as Lucentis in eye disease

May 4, 2011
Research and Development Lucentis, avastin, off label, wet AMD

Roche’s cancer drug Avastin is as effective at treating wet AMD as Novartis’ Lucentis, which is licensed for the eye …

News
Age-related macular degeneration (Wet AMD)

Bayer’s challenger to Lucentis shows promise

November 22, 2010
Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025